NCT02547870View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

August 14, 2015

Primary Completion Date

April 26, 2016

Study Completion Date

April 26, 2016

Conditions
Human Immunodeficiency Virus Type 1
Interventions
DRUG

Rilpivirine (RPV)

Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.

DRUG

Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)

Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.

DRUG

Aged RPV-LA

Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.

Trial Locations (1)

Unknown

Antwerp

All Listed Sponsors
lead

Janssen Infectious Diseases BVBA

INDUSTRY

NCT02547870 - A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics | Biotech Hunter | Biotech Hunter